Legal Opinion
Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.
Court of Appeals for the Federal Circuit
Decided December 3, 2014No. 2014-1391PublishedCited by 107 opinions
1Opinion of the Court
O’MALLEY, Circuit Judge.
This patent case involves methods of use of nanosized formulations of the drug megestrol acetate (“megestrol”). After a bench trial, the U.S. District Court for the District of Maryland found the asserted claims of U.S. Patent No. 7,101,576 (“'576 patent”) invalid as obvious. We vacate the district court’s judgment of invalidity and remand for further analysis because the district court incorrectly applied our law on inherency in the context of obviousness.
I
The '576 patent claims methods of using megestrol nanoparticles to “increas[e] the body mass in a human patient…
2Cases cited32 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Microsoft Corp. v. i4i Ltd. PartnershipSupreme Court of the United States · 2011
- Stratoflex, Inc. v. Aeroquip CorporationCourt of Appeals for the Federal Circuit · 1983
- In Re Robert J. Gartside and Richard C. NortonCourt of Appeals for the Federal Circuit · 2000
27 more not listed; retrieve them via the Exa API.
3Cited by107 opinions
- Arctic Cat Inc. v. Bombardier Recreational Products Inc.Court of Appeals for the Federal Circuit · 2017
- Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd.Court of Appeals for the Federal Circuit · 2016
- Apple Inc. v. Samsung Electronics Co., Ltd.Court of Appeals for the Federal Circuit · 2016
- Ariosa Diagnostics v. Verinata Health, Inc.Court of Appeals for the Federal Circuit · 2015
- Redline Detection, LLC v. Star Envirotech, Inc.Court of Appeals for the Federal Circuit · 2015
102 more not listed; retrieve them via the Exa API.